122 related articles for article (PubMed ID: 19452490)
1. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction.
Dominguez-Rodriguez A; Abreu-Gonzalez P
Clin Cardiol; 2009 May; 32(5):288. PubMed ID: 19452490
[No Abstract] [Full Text] [Related]
2. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction.
Tan J; Hua Q; Gao J; Fan ZX
Clin Cardiol; 2008 Sep; 31(9):413-8. PubMed ID: 18781600
[TBL] [Abstract][Full Text] [Related]
3. Correlations between serum inflammation factors and left ventricular remodeling in acute ST segment elevation myocardial infarction.
Tan J; Hua Q
Yonsei Med J; 2012 May; 53(3):501-7. PubMed ID: 22476992
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial infarction.
Tan J; Hua Q; Li J; Fan Z
Heart Vessels; 2009 Sep; 24(5):329-34. PubMed ID: 19784814
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor [corrected] of matrix metalloproteinase-1 in myocardial infarction.
Guzel S; Serin O; Guzel EC; Buyuk B; Yılmaz G; Güvenen G
Korean J Intern Med; 2013 Mar; 28(2):165-73. PubMed ID: 23525523
[TBL] [Abstract][Full Text] [Related]
6. Association of matrix metalloproteinase-1, matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1, and interleukin-6 with epicardial and myocardial perfusion.
Tanindi A; Sahinarslan A; Elbeg S; Cemri M
Coron Artery Dis; 2011 Jun; 22(4):253-8. PubMed ID: 21317638
[TBL] [Abstract][Full Text] [Related]
7. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
8. Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction.
Li J; Zhao SP; Peng DQ; Xu ZM; Zhou HN
Clin Chem; 2004 Sep; 50(9):1696-9. PubMed ID: 15265816
[No Abstract] [Full Text] [Related]
9. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
[TBL] [Abstract][Full Text] [Related]
10. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I.
Manginas A; Bei E; Chaidaroglou A; Degiannis D; Koniavitou K; Voudris V; Pavlides G; Panagiotakos D; Cokkinos DV
Clin Cardiol; 2005 Apr; 28(4):182-6. PubMed ID: 15869050
[TBL] [Abstract][Full Text] [Related]
11. Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation.
Dominguez-Rodriguez A; Abreu-Gonzalez P; Garcia-Gonzalez MJ; Kaski JC
Thromb Res; 2009 Feb; 123(4):617-21. PubMed ID: 18579184
[TBL] [Abstract][Full Text] [Related]
12. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction.
Squire IB; Evans J; Ng LL; Loftus IM; Thompson MM
J Card Fail; 2004 Aug; 10(4):328-33. PubMed ID: 15309700
[TBL] [Abstract][Full Text] [Related]
13. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
14. Novel inflammatory biomarkers in acute coronary syndrome.
Sim DS; Ahn Y
Korean J Intern Med; 2013 Mar; 28(2):156-8. PubMed ID: 23526870
[No Abstract] [Full Text] [Related]
15. Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction.
Ohashi Y; Kawashima S; Mori T; Terashima M; Ichikawa S; Ejiri J; Awano K
Int J Cardiol; 2006 Sep; 112(1):52-8. PubMed ID: 16376442
[TBL] [Abstract][Full Text] [Related]
16. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
17. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome.
Gibson CM; Karmpaliotis D; Kosmidou I; Murphy SA; Kirtane AJ; Budiu D; Ray KK; Herrmann HC; Lakkis N; Kovach R; French W; Blankenship J; Lui HH; Palabrica T; Jennings LK; Cohen DJ; Morrow DA;
Am J Cardiol; 2006 May; 97(10):1473-7. PubMed ID: 16679086
[TBL] [Abstract][Full Text] [Related]
18. [Changes and relations of soluble plasma CD40L and matrix metalloproteinase-9 levels in patients with coronary heart disease].
Li J; Zhao SP; Peng DQ; Zhou HN
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Oct; 29(5):517-20. PubMed ID: 16137036
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction.
Dominguez-Rodriguez A; Abreu-Gonzalez P; Garcia-Gonzalez MJ; Kaski JC
Thromb Res; 2007; 121(3):293-9. PubMed ID: 17521712
[TBL] [Abstract][Full Text] [Related]
20. Comparison of inflammatory markers between diabetic and nondiabetic ST segment elevation myocardial infarction.
Heo JM; Park JH; Kim JH; You SH; Kim JS; Ahn CM; Hong SJ; Shin KH; Lim DS
J Cardiol; 2012 Sep; 60(3):204-9. PubMed ID: 22658696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
